Durable Response to Pazopanib in a Patient with Fumarate Hydratase-Mutant Tubulocystic Renal Cell Carcinoma

Anjum Othman*, Shiyam Kumar, Asim Qureshi, Zabah M. Jawa, Ikram A. Burney

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Tubulocystic carcinoma of the kidney (TC-RCC) is a rare renal tumor and has been recently included as a distinct entity in WHO classification of renal neoplasms. We report the case of a patient with metastatic tubulocystic RCC whose disease progressed through standard of care treatment for nonclear RCC. However, genetic analysis revealed a germline pathogenic variant of fumarate hydratase (FH) gene, and the patient had a sustained and durable response to pazopanib.

Original languageEnglish
Pages (from-to)234-242
Number of pages9
JournalCase Reports in Oncology
Publication statusAccepted/In press - 2023


  • Fumarate hydrogenase
  • Genomic profiling
  • Pazopanib
  • Precision oncology
  • Renal cell carcinoma
  • Tubulocystic

ASJC Scopus subject areas

  • Oncology

Cite this